Photobiomodulation Therapy for Chemotherapy Hair Loss

Photobiomodulation Therapy in the Prevention and Management of Chemotherapy-Induced Alopecia

Recruiting N/A Interventional Study
Chemotherapy-induced Alopecia
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Female
Study type
Interventional
Purpose
Prevention
Participants needed
72 (estimated)
Sponsor
Jessa Hospital · Other
Who this trial is looking for

This trial is looking for patients with gynecological or breast cancer who are experiencing hair loss due to chemotherapy. Participants will receive a specific light therapy to help manage this hair loss.

Are You a Good Fit for This Trial?
Rules you out Substance abuseUnstable medical condition

You may be able to join if

  • I have been diagnosed with gynecological cancer or breast cancer.
  • I am receiving chemotherapy.
  • I am 18 years or older.
  • I can follow the study instructions.
  • I can sign a written consent form.

You may not be able to join if

  • I have metastatic cancer.
  • I am pregnant.
  • I currently have an infection on my scalp.
  • I have been diagnosed with a hair loss condition before.
  • My chemotherapy has been interrupted for more than two cycles.
  • I take medication to promote hair growth.
  • I have a severe psychological disorder or dementia.
  • I cannot speak or understand Dutch.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This study aims to investigate the effectiveness of photobiomodulation therapy (PBM) in the prevention and management of chemotherapy-induced alopecia (CIA). Therefore, we hypothesize that PBMT can reduce the severity of CIA in gynecological and breast cancer patients, increasing the patient's QoL.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Diagnosed with gynecological cancer (endometrium, cervix, ovarian or vulva) or breast cancer * Receiving chemotherapy ((Carbo)-Taxol) * Age ≥ 18 years * Able to comply to the study protocol * Able to sign written informed consent Exclusion Criteria: * Metastatic disease * Pr…
Contacts

Jeroen Mebis, Prof. Dr.

+32 11 33 72 21

jeroen.mebis@jessazh.be

CONTACT

Marithé Claes, MSc

+32 11 33 72 39

marithe.claes@uhasselt.be

CONTACT